T he major biological actions of the renin-angiotensin system are mediated by angiotensin (Ang) II, which binds with equal affinity to Ang type 1 (AT 1 ) and type 2 (AT 2 ) receptors. The majority of Ang II actions, however, are mediated by the AT 1 receptor, including vasoconstriction, cellular proliferation, tissue growth, direct renal tubular sodium reabsorption, sympathetic nervous stimulation, and aldosterone secretion, which, in aggregate, lead to a rise in blood pressure. 1 Because the AT 1 receptor is expressed ubiquitously in relatively high levels at renal and cardiovascular sites, an increase in blood pressure represents the net response to increased circulating Ang II.By contrast, AT 2 receptors carry a relatively low level of tissue expression in the adult compared with that of AT 1 receptors. 1 AT 2 receptors are expressed in large quantities in fetal tissues, but their expression decreases in the neonatal period and reaches a comparatively low level in the adult animal. However, the capacity for AT 2 receptor re-expression is retained in the adult, because upregulation is a common response to circumstances of cardiovascular tissue damage, such as myocardial infarction, heart failure, and hypertension.Activation of AT 2 receptors by the binding of Ang II stimulates a hormonal cascade consisting of bradykinin (BK), NO, and cGMP, leading to vasodilation that is counterregulatory to the vasoconstriction induced by Ang II via AT 1 receptors. 2 AT 2 receptor-induced vasodilation has been unequivocally demonstrated in both resistance and capacitance vessels. 3,4 In capacitance vessels, Ang II binding to the AT 2 receptor activates the BK B 2 receptor, stimulating the phosphorylation of endothelial NO synthase at its serine 633 and serine 1177 residues by a protein kinase A-dependent mechanism, inducing NO generation. 4 In mesenteric, uterine, and coronary small resistance arteries, Ang II-induced vasodilation is mediated by the BK/NO/cGMP pathway and is not subject to desensitization, as is AT 1 receptor-mediated vasoconstriction. In whole-animal studies, in the presence of AT 1 receptor blockade, Ang II induces sustained vasodilation and hypotension that is abolished by AT 2 receptor antagonist PD-123319 and is mediated by the BK/NO/cGMP pathway. 5,6 Thus, it is now generally accepted that the AT 2 receptor induces counterregulatory vasodilation that opposes AT 1 receptor-mediated vasoconstriction.Because AT 2 receptor expression is developmentally regulated, and its activation has been described as inhibitory to flow-mediated dilation in hypertensive animals, Pinaud et al,7 in this issue, hypothesized that AT 2 receptor function might behave differently in the resistance arteries of aged rats compared with nonaged control adult rats. As expected, their results show that resistance arteries from old rats had lower flow-and NO-mediated vasodilation and lower endothelial NO synthase expression than that of young control rats. However, a surprising finding was that, in old rats, AT 2 receptor blockade impr...